Glucagon-like peptide-1 (GLP-1) receptor agonist can reduce mortality and improve cardiovascular outcomes among patients with type 2 diabetes and end-stage kidney disease, compared to dipeptidyl peptidase -4 inhibitor use.
Read More »Can a Calorie-Restricted Diet Improve Long-Term Progressive Kidney Function Decline?
Studies have found that there may be a benefit in implementing a calorie-restricted diet in patients with type 2 diabetes to improve glomerular hyperfiltration.
Read More »Dapagliflozin is a Potential Treatment Option for Chronic Kidney Disease Patients
DAPA-CKD trial results indicate a significant benefit for SGLT2 inhibitor dapagliflozin in reducing chronic kidney disease progression and mortality caused by kidney failure and cardiovascular disease, regardless of diabetes status.
Read More »The Benefit of Intensive Albuminuria Lowering In Patients With Type 2 Diabetes
Hyperuricemia has been implicated in the development and progression of chronic kidney disease, and the effects of intensive albuminuria lowering may be beneficial.
Read More »Finerenone Use In Patients With CKD and Type 2 Diabetes
According to research presented by Dr. George Bakris of the University of Chicago, treatment with finerenone resulted in a lower risk of the progression of chronic kidney disease and cardiovascular events.
Read More »Dapagliflozin Gets Nod as a Breakthrough Therapy Designation for CKD
Dapagliflozin (Farxiga®) has been granted U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation (BTD) for patients with chronic kidney disease (CKD), whether or not they have type 2 diabetes.
Read More »Evaluation of CVD/CKD Risks in Patients with Type 2 Diabetes
Despite being on first-line oral anti-diabetic drug therapy, the risk of developing CVD/CKD in patients with type 2 diabetes remains high.
Read More »Efpeglenatide Has Cardiovascular and Renal Benefit Outcomes in Type 2 Diabetes
Efpeglenatide has proven to significantly reduce several risk factors for cardiovascular and kidney disease.
Read More »Canagliflozin’s Renal and Cardiovascular Benefits in People with Heart Failure
CREDENCE trial shows that canagliflozin, an SGLT2 inhibitor, lowers the risk of cardiovascular and renal events in patients with T2DM, regardless of prior history of heart failure.
Read More »An Update on the Benefits of GLP-1 Receptor Agonists for Type 2 Diabetes
GLP-1 receptor agonists are a pharmacologic treatment of type 2 diabetes with potential cardiorenal benefits.
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.